Benoquin

Vitiligo, Vitiligo
Treatment
7 Active Studies for Benoquin

What is Benoquin

MonobenzoneThe Generic name of this drug
Treatment SummaryMonobenzone is a medication used to cause skin lightening in people with abnormal discoloration of the skin. It is a white, nearly flavorless powder that dissolves in alcohol and is mostly insoluble in water. Monobenzone works by removing melanin from the skin and can cause permanent lightening. It may also destroy the cells that produce melanin.
Benoquinis the brand name
image of different drug pills on a surface
Benoquin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Benoquin
Monobenzone
2017
1

Effectiveness

How Benoquin Affects PatientsMonobenzone is a cream that is used to lighten dark spots on the skin. It works by blocking the production of melanin, which is responsible for giving skin its color. When applied to the area surrounding skin with vitiligo, monobenzone will permanently remove color from that area.
How Benoquin works in the bodyMonobenzone works to lighten the skin by increasing the amount of melanin that is let out of the skin cells. It may take a few months to see results, and sunlight can reduce the effect. After use, the skin typically looks similar to skin with vitiligo, where melanocytes are not present.

When to interrupt dosage

The proposed dosage of Benoquin is contingent upon the identified condition. The measure of dosage shifts with the technique of application (e.g. Topical or Cream - Topical) featured in the table underneath.
Condition
Dosage
Administration
Vitiligo
, 20.0 %, 200.0 mg/mL, 0.2 mg/mg
, Topical, Cream - Topical, Cream
Vitiligo
, 20.0 %, 200.0 mg/mL, 0.2 mg/mg
, Topical, Cream - Topical, Cream

Warnings

Benoquin has two contraindications, thus it should not be taken while experiencing any of the conditions presented in the table below.Benoquin Contraindications
Condition
Risk Level
Notes
Vitiligo
Do Not Combine
hydroquinone
Do Not Combine
There are 1 known major drug interactions with Benoquin.
Common Benoquin Drug Interactions
Drug Name
Risk Level
Description
Agalsidase alfa
Moderate
The therapeutic efficacy of Agalsidase alfa can be decreased when used in combination with Monobenzone.

Benoquin Novel Uses: Which Conditions Have a Clinical Trial Featuring Benoquin?

16 active trials are being conducted to assess the utility of Benoquin in Skin depigmentation.
Condition
Clinical Trials
Trial Phases
Vitiligo
0 Actively Recruiting
Vitiligo
7 Actively Recruiting
Phase 2, Phase 3, Phase 1

Patient Q&A Section about benoquin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you get pentoxifylline over the counter?

"Pentoxifylline can only be obtained through a doctor's prescription."

Answered by AI

Where should you not store medicine?

"You can store medicine in a storage box, on a shelf, in a closet, or in a bathroom cabinet. However, the heat and moisture from your shower, bath, and sink may damage your medicine."

Answered by AI

How do you Depigment vitiligo?

"The lotion usually needs to be applied once or twice daily, and the treatment continues for 12 to 18 months.

Depigmentation therapy may be recommended by a doctor to people with vitiligo who have lost pigment on more than 50% of their bodies. Although the therapy may not be widely available, it involves painting a lotion onto the remaining normal skin to bleach the remaining pigment so that it becomes the same color as the depigmented areas (White). The lotion is typically applied once or twice daily, and the therapy takes 12 to 18 months."

Answered by AI

Can I buy medicine online?

"You can buy almost anything you want on the internet, even prescription drugs. It's convenient to have your medicine delivered to your house when you order it online, but this service may come at an extra cost."

Answered by AI

Clinical Trials for Benoquin

Image of Marvel Clinical Research in Huntington Beach, United States.

Ritlecitinib for Vitiligo

Any Age
All Sexes
Huntington Beach, CA
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo) * Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study * Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study. This study is seeking for participants who: * have non-segmental vitiligo (either active or stable) and * received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it. All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home. Participants may receive the study medicine or placebo for up to 52 weeks. The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo. Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study. Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.
Phase 3
Recruiting
Marvel Clinical Research (+34 Sites)Pfizer CT.gov Call CenterPfizer
Image of Michigan Center for Research Company /ID# 260069 in Clarkston, United States.

Upadacitinib for Vitiligo

Any Age
All Sexes
Clarkston, MI
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed. Upadacitinib is an approved drug for various immune-mediated inflammatory diseases and is currently being investigated for the treatment of NSV. There will be 2 replicate studies running at the same time (Study 1 and Study 2 with periods A and B) and an optional exploratory Narrow-Band Ultraviolet B (NB-UVB) phototherapy study (Study 3). In Period A, participants are placed in 1 of 2 groups called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will receive placebo and 2 in 3 chance participants will receive upadacitinib. In Period B, all participants will receive upadacitinib. Approximately 270 adult and adolescent participants with NSV will be enrolled in each main study ((Study 1 and Study 2, 540 subjects total) at approximately 90 sites worldwide with an option for adult participants who completed Period A of either study and did not achieve T-VASI 90 at week 48 while on study drug, to enter Study 3. In Studies 1 and 2: Period A, participants will receive oral tablets of upadacitinib or placebo once a day for 48 weeks. In Period B, participants will receive oral tablets of upadacitinib 15 mg once a day for 112 weeks. Participants will be followed up for 30 days. Study 3 participants will receive upadacitinib monotherapy or upadacitinib with NB-UBV phototherapy for at least 24 weeks followed by upadacitinib alone. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 3
Waitlist Available
Quick Reply
Michigan Center for Research Company /ID# 260069 (+65 Sites)ABBVIE INC.AbbVie
Have you considered Benoquin clinical trials? We made a collection of clinical trials featuring Benoquin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security